Exacerbation Rate Reduction With Mepolizumab Stratified by Maintenance Oral Corticosteroids Use and Eosinophil Levels: A Post Hoc Analysis of the DREAM and MENSA Studies

Bobolea, I; Bañas, D; Melero, C; Andrés, A. de I; Joksaite, S; Sánchez-Herrero, G

Bobolea, I; Bañas, D; Melero, C; Andrés, A. de I; Joksaite, S; Sánchez-Herrero, G.

Affiliation

Bobolea, I; Hospital Clinic BarcelonaInstitute for Health. Department of Pulmonology. Severe Asthma Unit. Barcelona. Spain
Bañas, D; GSK. Madrid. Spain
Melero, C; Hospital 12 de Octubre Institute for Health Research. Madrid. Spain
Andrés, A. de I; GSK. Madrid. Spain
Joksaite, S; GSK. Madrid. Spain
Sánchez-Herrero, G; GSK. Madrid. Spain

J. investig. allergol. clin. immunol ; 32(2): 148-150, 2022. tab

Article in En | IBECS | ID: ibc-203907

Responsible library: ES1.1

Localization: ES15.1 - BNCS

Subject(s)

Humans; Randomized Controlled Trials as Topic; Asthma/drug therapy; Eosinophilia/drug therapy; Antibodies, Monoclonal, Humanized/administration & dosage; Adrenal Cortex Hormones/administration & dosage

Key words

Asthma; Eosinophils; Exacerbations; Mepolizumab; Oral corticosteroids (OCS); Asma; Eosinófilos; Exacerbaciones; Mepolizumab; Corticoesteroides orales (CO)

Fulltext

XML

Search on Google

Full text: 1 Collection: 06-national / ES Database: IBECS Main subject: Asthma / Randomized Controlled Trials as Topic / Adrenal Cortex Hormones / Eosinophilia / Antibodies, Monoclonal, Humanized Limits: Humans Language: En Journal: J. investig. allergol. clin. immunol Year: 2022 Type: Article

Fulltext

XML

Search on Google